{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T17:47:34Z","timestamp":1769276854473,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Klin Intensivmed Notfmed"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00063-023-01051-6","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T19:01:38Z","timestamp":1693335698000},"page":"470-476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antiinfektive Therapie von Pilzinfektionen durch Candida und Aspergillus","Anti-infective treatment of fungal infections by Candida and Aspergillus"],"prefix":"10.1007","volume":"118","author":[{"given":"Helmut J. F.","family":"Salzer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"issue":"1","key":"1051_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s13054-019-2497-3","volume":"23","author":"M Bassetti","year":"2019","unstructured":"Bassetti\u00a0M, Giacobbe\u00a0DR, Vena\u00a0A, Trucchi\u00a0C, Ansaldi\u00a0F, Antonelli\u00a0M et\u00a0al (2019) Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Crit Care 23(1):219. https:\/\/doi.org\/10.1186\/s13054-019-2497-3","journal-title":"Crit Care"},{"issue":"3","key":"1051_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/myc.13211","volume":"64","author":"CL Keighley","year":"2021","unstructured":"Keighley\u00a0CL, Pope\u00a0A, Marriott\u00a0DJE, Chapman\u00a0B, Bak\u00a0N, Daveson\u00a0K et al (2021) Risk factors for candidaemia: a prospective multi-centre case-control study. Mycoses 64(3):257\u2013263. https:\/\/doi.org\/10.1111\/myc.13211","journal-title":"Mycoses"},{"issue":"6","key":"1051_CR3","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S1473-3099(22)00872-6","volume":"23","author":"M Hoenigl","year":"2023","unstructured":"Hoenigl\u00a0M, Salmanton-Garcia\u00a0J, Egger\u00a0M, Gangneux\u00a0JP, Bicanic\u00a0T, Arikan-Akdagli\u00a0S et al (2023) Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study. Lancet Infect Dis 23(6):751\u2013761. https:\/\/doi.org\/10.1016\/S1473-3099(22)00872-6","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"1051_CR4","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","volume":"62","author":"PG Pappas","year":"2016","unstructured":"Pappas\u00a0PG, Kauffman\u00a0CA, Andes\u00a0DR, Clancy\u00a0CJ, Marr\u00a0KA, Ostrosky-Zeichner\u00a0L et al (2016) Clinical practice guideline for the management of Candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis 62(4):e1\u2013e50. https:\/\/doi.org\/10.1093\/cid\/civ933","journal-title":"Clin Infect Dis"},{"issue":"Suppl 7","key":"1051_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1469-0691.12039","volume":"18","author":"OA Cornely","year":"2012","unstructured":"Cornely\u00a0OA, Bassetti\u00a0M, Calandra\u00a0T, Garbino\u00a0J, Kullberg\u00a0BJ, Lortholary\u00a0O et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18(Suppl 7):19\u201337. https:\/\/doi.org\/10.1111\/1469-0691.12039","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"1051_CR6","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1111\/myc.13274","volume":"64","author":"JD Jenks","year":"2021","unstructured":"Jenks\u00a0JD, Nam\u00a0HH, Hoenigl\u00a0M (2021) Invasive aspergillosis in critically ill patients: review of definitions and diagnostic approaches. Mycoses 64(9):1002\u20131014. https:\/\/doi.org\/10.1111\/myc.13274","journal-title":"Mycoses"},{"issue":"6","key":"1051_CR7","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donelly","year":"2020","unstructured":"Donelly JP, Chen SC, Kauffman CA et al (2020) Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis 71(6):1367\u20131376. https:\/\/doi.org\/10.1093\/cid\/ciz1008","journal-title":"Clin Infect Dis"},{"issue":"8","key":"1051_CR8","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/myc.13478","volume":"65","author":"M Schroeder","year":"2022","unstructured":"Schroeder\u00a0M, Giese\u00a0M, Wijaya\u00a0C, Winterland\u00a0S, Nuechtern\u00a0A, Grensemann\u00a0J et\u00a0al (2022) Comparison of four diagnostic criteria for invasive pulmonary aspergillosis\u2014a diagnostic accuracy study in critically ill patients. Mycoses 65(8):824\u2013833. https:\/\/doi.org\/10.1111\/myc.13478","journal-title":"Mycoses"},{"issue":"Suppl 2","key":"1051_CR9","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1093\/cid\/ciaa1751","volume":"72","author":"M Bassetti","year":"2021","unstructured":"Bassetti\u00a0M, Azoulay\u00a0E, Kullberg\u00a0BJ, Ruhnke\u00a0M, Shoham\u00a0S, Vazquez\u00a0J et\u00a0al (2021) EORTC\/MSGERC definitions of invasive fungal diseases: summary of activities of the intensive care unit working group. Clin Infect Dis 72(Suppl 2):S121\u2013S127. https:\/\/doi.org\/10.1093\/cid\/ciaa1751","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"1051_CR10","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","volume":"24","author":"AJ Ullmann","year":"2018","unstructured":"Ullmann\u00a0AJ, Aguado\u00a0JM, Arikan-Akdagli\u00a0S, Denning\u00a0DW, Groll\u00a0AH, Lagrou\u00a0K et al (2018) Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 24(Suppl 1):e1\u2013e38. https:\/\/doi.org\/10.1016\/j.cmi.2018.01.002","journal-title":"Clin Microbiol Infect"},{"issue":"10273","key":"1051_CR11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","volume":"397","author":"JA Maertens","year":"2021","unstructured":"Maertens\u00a0JA, Rahav\u00a0G, Lee\u00a0DG, Ponce-de-Leon\u00a0A, Ramirez Sanchez\u00a0IC, Klimko\u00a0N et al (2021) Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a\u00a0phase\u00a03, randomised, controlled, non-inferiority trial. Lancet 397(10273):499\u2013509. https:\/\/doi.org\/10.1016\/S0140-6736(21)00219-1","journal-title":"Lancet"},{"key":"1051_CR12","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.2147\/IDR.S372546","volume":"16","author":"M Egger","year":"2023","unstructured":"Egger\u00a0M, Bellmann\u00a0R, Krause\u00a0R, Boyer\u00a0J, Jaksic\u00a0D, Hoenigl\u00a0M (2023) Salvage treatment for invasive Aspergillosis and Mucormycosis: challenges, recommendations and future considerations. Infect Drug Resist 16:2167\u20132178. https:\/\/doi.org\/10.2147\/IDR.S372546","journal-title":"Infect Drug Resist"},{"key":"1051_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s13054-021-03753-9","volume":"25","author":"S Hatzl","year":"2021","unstructured":"Hatzl S, Reisinger AC, Posch F et al (2021) Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: an observational study. Crit Care 25:335. https:\/\/doi.org\/10.1186\/s13054-021-03753-9","journal-title":"Crit Care"},{"key":"1051_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-023-00727-z","author":"J Boyer","year":"2023","unstructured":"Boyer\u00a0J, Feys\u00a0S, Zsifkovits\u00a0I, Hoenigl\u00a0M, Egger\u00a0M (2023) Treatment of invasive Aspergillosis: how it\u2019s going, where it\u2019s heading. Mycopathologia. https:\/\/doi.org\/10.1007\/s11046-023-00727-z","journal-title":"Mycopathologia"},{"key":"1051_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/jof7050378","author":"O Georgacopoulos","year":"2021","unstructured":"Georgacopoulos\u00a0O, Nunnally\u00a0NS, Ransom\u00a0EM, Law\u00a0D, Birch\u00a0M, Lockhart\u00a0SR et\u00a0al (2021) In vitro activity of novel antifungal Olorofim against filamentous fungi and comparison to eight other antifungal agents. J\u00a0Fungi (Basel). https:\/\/doi.org\/10.3390\/jof7050378","journal-title":"J Fungi (Basel)"},{"issue":"5","key":"1051_CR16","doi-asserted-by":"publisher","first-page":"e0141922","DOI":"10.1128\/aac.01419-22","volume":"67","author":"JA Vazquez","year":"2023","unstructured":"Vazquez\u00a0JA, Pappas\u00a0PG, Boffard\u00a0K, Paruk\u00a0F, Bien\u00a0PA, Tawadrous\u00a0M et\u00a0al (2023) Clinical efficacy and safety of a\u00a0novel antifungal, Fosmanogepix, in patients with Candidemia caused by Candida auris: results from a\u00a0phase\u00a02 trial. Antimicrob Agents Chemother 67(5):e141922. https:\/\/doi.org\/10.1128\/aac.01419-22","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"1051_CR17","doi-asserted-by":"publisher","first-page":"e0038022","DOI":"10.1128\/aac.00380-22","volume":"66","author":"T Gebremariam","year":"2022","unstructured":"Gebremariam\u00a0T, Gu\u00a0Y, Alkhazraji\u00a0S, Youssef\u00a0E, Shaw\u00a0KJ, Ibrahim\u00a0AS (2022) The combination treatment of Fosmanogepix and Liposomal Amphotericin B is superior to monotherapy in treating experimental invasive mold infections. Antimicrob Agents Chemother 66(7):e38022. https:\/\/doi.org\/10.1128\/aac.00380-22","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"1051_CR18","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1093\/jac\/dkz302","volume":"74","author":"T Colley","year":"2019","unstructured":"Colley\u00a0T, Sharma\u00a0C, Alanio\u00a0A, Kimura\u00a0G, Daly\u00a0L, Nakaoki\u00a0T et al (2019) Anti-fungal activity of a\u00a0novel triazole, PC1244, against emerging azole-resistant Aspergillus fumigatus and other species of Aspergillus. J\u00a0Antimicrob Chemother 74(10):2950\u20132958. https:\/\/doi.org\/10.1093\/jac\/dkz302","journal-title":"J Antimicrob Chemother"},{"issue":"10370","key":"1051_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","volume":"401","author":"GR Thompson 3rd","year":"2023","unstructured":"Thompson\u00a0GR 3rd, Soriano\u00a0A, Cornely\u00a0OA, Kullberg\u00a0BJ, Kollef\u00a0M, Vazquez\u00a0J et al (2023) Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a\u00a0multicentre, double-blind, double-dummy, randomised phase\u00a03\u00a0trial. Lancet 401(10370):49\u201359. https:\/\/doi.org\/10.1016\/S0140-6736(22)02324-8","journal-title":"Lancet"},{"issue":"4","key":"1051_CR20","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.cmi.2021.08.014","volume":"28","author":"J Prattes","year":"2022","unstructured":"Prattes\u00a0J, Wauters\u00a0J, Giacobbe\u00a0DR, Salmanton-Garcia\u00a0J, Maertens\u00a0J, Bourgeois\u00a0M et al (2022) Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients\u2014a multinational observational study by the European Confederation of Medical Mycology. Clin Microbiol Infect 28(4):580\u2013587. https:\/\/doi.org\/10.1016\/j.cmi.2021.08.014","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"1051_CR21","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1016\/S1473-3099(20)30847-1","volume":"21","author":"P Koehler","year":"2021","unstructured":"Koehler\u00a0P, Bassetti\u00a0M, Chakrabarti\u00a0A, Chen\u00a0SCA, Colombo\u00a0AL, Hoenigl\u00a0M et al (2021) Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis 21(6):e149\u2013e162. https:\/\/doi.org\/10.1016\/S1473-3099(20)30847-1","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"1051_CR22","doi-asserted-by":"publisher","first-page":"e3606","DOI":"10.1093\/cid\/ciaa1065","volume":"73","author":"M Bartoletti","year":"2021","unstructured":"Bartoletti\u00a0M, Pascale\u00a0R, Cricca\u00a0M, Rinaldi\u00a0M, Maccaro\u00a0A, Bussini\u00a0L et al (2021) Epidemiology of invasive pulmonary Aspergillosis among intubated patients with COVID-19: a prospective study. Clin Infect Dis 73(11):e3606\u2013e3614. https:\/\/doi.org\/10.1093\/cid\/ciaa1065","journal-title":"Clin Infect Dis"},{"key":"1051_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/jof7050388","author":"F Reizine","year":"2021","unstructured":"Reizine\u00a0F, Pinceaux\u00a0K, Lederlin\u00a0M, Autier\u00a0B, Guegan\u00a0H, Gacouin\u00a0A et al (2021) Influenza- and COVID-19-associated pulmonary Aspergillosis: are the pictures different? J\u00a0Fungi (Basel). https:\/\/doi.org\/10.3390\/jof7050388","journal-title":"J Fungi (Basel)"},{"issue":"6","key":"1051_CR24","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00134-021-06431-0","volume":"47","author":"L Vanderbeke","year":"2021","unstructured":"Vanderbeke\u00a0L, Janssen\u00a0NAF, Bergmans\u00a0D, Bourgeois\u00a0M, Buil\u00a0JB, Debaveye\u00a0Y et al (2021) Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a\u00a0randomised, open-label, proof-of-concept trial. Intensive Care Med 47(6):674\u2013686. https:\/\/doi.org\/10.1007\/s00134-021-06431-0","journal-title":"Intensive Care Med"},{"issue":"2","key":"1051_CR25","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/myc.12589","volume":"60","author":"HJ Salzer","year":"2017","unstructured":"Salzer\u00a0HJ, Heyckendorf\u00a0J, Kalsdorf\u00a0B, Rolling\u00a0T, Lange\u00a0C (2017) Characterization of patients with chronic pulmonary aspergillosis according to the new ESCMID\/ERS\/ECMM and IDSA guidelines. Mycoses 60(2):136\u2013142. https:\/\/doi.org\/10.1111\/myc.12589","journal-title":"Mycoses"},{"key":"1051_CR26","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01062-2016","author":"D Lowes","year":"2017","unstructured":"Lowes\u00a0D, Al-Shair\u00a0K, Newton\u00a0PJ, Morris\u00a0J, Harris\u00a0C, Rautemaa-Richardson\u00a0R et al (2017) Predictors of mortality in chronic pulmonary aspergillosis. Eur Respir\u00a0J. https:\/\/doi.org\/10.1183\/13993003.01062-2016","journal-title":"Eur Respir J"},{"issue":"2","key":"1051_CR27","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000489474","volume":"96","author":"A Alastruey-Izquierdo","year":"2018","unstructured":"Alastruey-Izquierdo\u00a0A, Cadranel\u00a0J, Flick\u00a0H, Godet\u00a0C, Hennequin\u00a0C, Hoenigl\u00a0M et al (2018) Treatment of Chronic Pulmonary Aspergillosis: Current Standards and Future Perspectives. Respiration 96(2):159\u2013170. https:\/\/doi.org\/10.1159\/000489474","journal-title":"Respiration"}],"container-title":["Medizinische Klinik - Intensivmedizin und Notfallmedizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-023-01051-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00063-023-01051-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-023-01051-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T15:17:38Z","timestamp":1694704658000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00063-023-01051-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1051"],"URL":"https:\/\/doi.org\/10.1007\/s00063-023-01051-6","relation":{},"ISSN":["2193-6218","2193-6226"],"issn-type":[{"value":"2193-6218","type":"print"},{"value":"2193-6226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,29]]},"assertion":[{"value":"4 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"H.J.F.\u00a0Salzer gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}